OpenAI Acquires Biotech Startup as AI Race Expands Into Drug Development

OpenAI has acquired Orchestra Bio, a biotechnology startup that develops AI agents to help pharmaceutical companies manage drug development.

As TodayPress TV reports, citing Axios, OpenAI will integrate the startup’s team and technology into Rosalind, its suite of AI models and tools designed for life sciences researchers.

Orchestra Bio’s platform allows scientists to delegate tasks such as monitoring studies, tracking drug development timelines and identifying potential delays to AI agents.

Both companies aim to connect scientific discoveries with the decisions and next steps needed to advance potential treatments.

The financial terms of the acquisition have not been disclosed.

Competition in artificial intelligence is expanding beyond coding and cybersecurity into scientific research. OpenAI and its rival Anthropic are both working to broaden the applications of their technologies.

In April, OpenAI introduced GPT-Rosalind, a specialized model designed to help researchers tackle complex problems in biology, chemistry and drug discovery. The company has also partnered with pharmaceutical giants Novo Nordisk and Moderna to integrate AI into research and development workflows.

OpenAI says developing a new medicine typically takes between ten and fifteen years. The company hopes artificial intelligence can help shorten that timeline.

Anthropic is also expanding its presence in life sciences. In June, the company launched Claude Science, a research platform that brings together scientific databases, analytical tools and specialized AI agents.

In September, Anthropic announced a new biological research lab. The company also said its Claude model had helped identify a previously unknown enzyme system with similarities to CRISPR. However, according to Bloomberg, some scientists argued that the significance of the findings had been overstated.

The developments highlight a broader shift in the AI race, as companies move beyond building increasingly powerful models and focus on applying AI across industries, including medicine and pharmaceuticals.

Gultaj Mehdizada